Omnitrope Related Published Studies
Well-designed clinical trials related to Omnitrope (Somatropin Subcutaneous)
Bioequivalence studies of omnitrope, the first biosimilar/rhGH follow-on protein: two comparative phase 1 randomized studies and population pharmacokinetic analysis. [2010.11]
Cost-effectiveness of somatropin for the treatment of short children born small for gestational age. [2010.06]
Bioequivalence between novel ready-to-use liquid formulations of the recombinant human GH Omnitrope and the original lyophilized formulations for reconstitution of Omnitrope and Genotropin. [2010.06]
Relative bioavailability of two drug products of somatropin obtained from either the milk of transgenic cows or bacterial culture. [2010]
Cost-effectiveness of somatropin for the treatment of short children born small
for gestational age. [2010]
Bioequivalence between novel ready-to-use liquid formulations of the recombinant
human GH Omnitrope and the original lyophilized formulations for reconstitution
of Omnitrope and Genotropin. [2010]
Effect of the inhaled corticosteroid mometasone on small airway patency in patients with asthma. [2009.05]
Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study. [2009]
Well-designed clinical trials possibly related to Omnitrope (Somatropin Subcutaneous)
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant
study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human
epidermal growth factor receptor 2-negative, operable breast cancer. [2014]
Endocrine therapy with or without inhibition of epidermal growth factor receptor
and human epidermal growth factor receptor 2: a randomized, double-blind,
placebo-controlled phase III trial of fulvestrant with or without lapatinib for
postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB
40302 (Alliance). [2014]
Ganitumab with either exemestane or fulvestrant for postmenopausal women with
advanced, hormone-receptor-positive breast cancer: a randomised, controlled,
double-blind, phase 2 trial. [2013]
Effects of midazolam and nitrous oxide on endocrine and metabolic measurements in
children. [2012]
OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients. [2011.12]
A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. [2011.09.08]
Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics. [2011.09]
Increased serum and bone matrix levels of transforming growth factor {beta}1 in patients with GH deficiency in response to GH treatment. [2011.09]
Effect of a high-protein diet on ghrelin, growth hormone, and insulin-like growth factor-I and binding proteins 1 and 3 in subjects with type 2 diabetes mellitus. [2011.09]
Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials. [2011.09]
Effect of intensive insulin therapy on the somatotropic axis of critically ill children. [2011.08]
Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. [2011.08]
Fasting, but not exercise, increases adipose triglyceride lipase (ATGL) protein and reduces G(0)/G(1) switch gene 2 (G0S2) protein and mRNA content in human adipose tissue. [2011.08]
Gender, sex-steroid, and secretagogue-selective recovery from growth hormone-induced feedback in older women and men. [2011.08]
Growth hormone (GH)-induced insulin resistance is rapidly reversible: an experimental study in GH-deficient adults. [2011.08]
Sleep after vaccination boosts immunological memory. [2011.07.01]
In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation. [2011.07]
Ghrelin modulates sympathetic nervous system activity and stress response in lean and overweight men. [2011.07]
Counter-regulatory hormone responses to spontaneous hypoglycaemia during treatment with insulin Aspart or human soluble insulin: a double-blinded randomized cross-over study. [2011.07]
Assessment of immune function after short-term administration of recombinant human growth hormone in healthy young males. [2011.07]
Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. [2011.06]
GH receptor blocker administration and muscle-tendon collagen synthesis in humans. [2011.06]
Complex regulation of GH autofeedback under dual-peptide drive: studies under a pharmacological GH and sex steroid clamp. [2011.06]
Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency. [2011.06]
Long-term response to GH therapy in short children with a delayed infancy-childhood transition (DICT). [2011.06]
Treatment with growth hormone, somatostatin, and insulin in combination with hypocaloric parenteral nutrition in gastrointestinal cancer patients after surgery. [2011.06]
Health-related quality of life of young adults with Turner syndrome following a long-term randomized controlled trial of recombinant human growth hormone. [2011.05.29]
Insulin and GH signaling in human skeletal muscle in vivo following exogenous GH exposure: impact of an oral glucose load. [2011.05.03]
A preliminary trial of the effect of recombinant human growth hormone on short-term linear growth and glucose homeostasis in children with Crohn's disease. [2011.05]
Levels of the epidermal growth factor-like peptide amphiregulin in follicular fluid reflect the mode of triggering ovulation: a comparison between gonadotrophin-releasing hormone agonist and urinary human chorionic gonadotrophin. [2011.05]
Leptin is an effective treatment for hypothalamic amenorrhea. [2011.04.19]
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. [2011.04]
Progesterone prevents sleep disturbances and modulates GH, TSH, and melatonin secretion in postmenopausal women. [2011.04]
Interaction between testosterone and growth hormone on whole-body protein anabolism occurs in the liver. [2011.04]
Effect of recombinant growth hormone on leptin, adiponectin, resistin, interleukin-6, tumor necrosis factor-alpha and ghrelin levels in growth hormone-deficient children. [2011.04]
Growth hormone plus childhood low-dose estrogen in Turner's syndrome. [2011.03.31]
Durability of the Effects of Testosterone and Growth Hormone Supplementation in Older Community Dwelling Men: The HORMA Trial. [2011.03.04]
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. [2011.03.01]
Effect of oral phosphate and alendronate on bone mineral density when given as adjunctive therapy to growth hormone replacement in adult growth hormone deficiency. [2011.03]
A diet high in meat protein and potential renal acid load increases fractional calcium absorption and urinary calcium excretion without affecting markers of bone resorption or formation in postmenopausal women. [2011.03]
Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency. [2011.03]
Effects of growth hormone and nutritional therapy in boys with constitutional growth delay: a randomized controlled trial. [2011.03]
Effects of ghrelin on psychopathology, sleep and secretion of cortisol and growth hormone in patients with major depression. [2011.03]
Effects of short-term treatment with orlistat on growth hormone/insulin-like growth factor-I axis in obese post-menopausal women. [2011.02]
Bolus arginine supplementation affects neither muscle blood flow nor muscle protein synthesis in young men at rest or after resistance exercise. [2011.02]
Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. [2011.02]
Effect of oxandrolone on glucose metabolism in growth hormone-treated girls with Turner syndrome. [2011.02]
Hormonal responses to resistance exercise after ingestion of carnosine and anserine. [2011.02]
Influence of acute aerobic exercise on adiponectin oligomer concentrations in middle-aged abdominally obese men. [2011.02]
Testosterone threshold levels and lean tissue mass targets needed to enhance skeletal muscle strength and function: the HORMA trial. [2011.01]
Effects of insulin-like growth factor-I administration on in vivo regulation of urea synthesis in normal subjects and patients with cirrhosis. [2011.01]
Interleukin 1 receptor antagonist is associated with changes in body composition during physiological GH substitution in patients with adult-onset growth hormone deficiency. [2011.01]
Moderate doses of hGH (0.64 mg/d) improve lipids but not cardiovascular function in GH-deficient adults with normal baseline cardiac function. [2011.01]
Effects of recombinant human growth hormone on protein turnover in the fasting and fed state in adolescents with Crohn disease. [2011]
The effects of short term recombinant human growth hormone (rhGH) on blood rheology in healthy young males. [2011]
Improvements in behaviour and self-esteem following growth hormone treatment in short prepubertal children. [2011]
Prospective study confirms oxandrolone-associated improvement in height in growth hormone-treated adolescent girls with Turner syndrome. [2011]
Serum IGF-1 concentrations change with soy and seaweed supplements in healthy postmenopausal American women. [2011]
Growth hormone plus childhood low-dose estrogen in Turner's syndrome. [2011]
Moderate doses of hGH (0.64 mg/d) improve lipids but not cardiovascular function
in GH-deficient adults with normal baseline cardiac function. [2011]
Treatment with growth hormone, somatostatin, and insulin in combination with
hypocaloric parenteral nutrition in gastrointestinal cancer patients after
surgery. [2011]
GH responses to two consecutive bouts of whole body vibration, maximal voluntary contractions or vibration alternated with maximal voluntary contractions administered at 2-h intervals in healthy adults. [2010.12]
Protein C and protein S changes in GH-deficient adults on r-HGH replacement therapy: correlations with PAI-1 and t-PA plasma levels. [2010.12]
Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. [2010.12]
Multiple doses of pegylated long-acting growth hormone are well tolerated in healthy male volunteers and possess a potential once-weekly treatment profile. [2010.12]
Serotonin function in pathological gambling: blunted growth hormone response to sumatriptan. [2010.12]
Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. [2010.11.16]
Evolution and resolution of human brain perfusion responses to the stress of induced hypoglycemia. [2010.11.01]
Effects of short term growth hormone therapy in adult growth hormone deficiency. [2010.11]
Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. [2010.11]
One year of growth hormone treatment in adults with Prader-Willi syndrome improves body composition: results from a randomized, placebo-controlled study. [2010.11]
Effects of testosterone administration on nocturnal cortisol secretion in healthy older men. [2010.11]
Effects of recombinant human growth hormone in anorexia nervosa: a randomized, placebo-controlled study. [2010.11]
Comparison of the pharmacokinetics, safety and tolerability of two concentrations of a new liquid recombinant human growth hormone formulation versus the freeze-dried formulation. [2010.10.20]
Intuitiveness, ease of use, and preference of a prefilled growth hormone injection pen: a noninterventional, randomized, open-label, crossover, comparative usability study of three delivery devices in growth hormone-treated pediatric patients. [2010.10]
Bioequivalence studies for three formulations of a recombinant human growth hormone: challenges and lessons learned. [2010.10]
Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus. [2010.10]
GH in combination with bisphosphonate treatment in osteogenesis imperfecta. [2010.09]
Exercise and fasting activate growth hormone-dependent myocellular signal transducer and activator of transcription-5b phosphorylation and insulin-like growth factor-I messenger ribonucleic acid expression in humans. [2010.09]
Effect of growth hormone replacement therapy on cognition after traumatic brain injury. [2010.09]
L-citrulline-malate influence over branched chain amino acid utilization during exercise. [2010.09]
The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease. [2010.09]
Growth hormone, prolactin and cortisol response to exercise in patients with depression. [2010.09]
Multiple doses of pegylated long-acting growth hormone is well tolerated in healthy male volunteers and possesses a potential once-weekly treatment profile. [2010.08.13]
The diagnosis and treatment of growth hormone deficiency in adults. [2010.08]
Comparative validation of the growth hormone-releasing hormone and arginine test for the diagnosis of adult growth hormone deficiency using a growth hormone assay conforming to recent international recommendations. [2010.08]
Individual exercise sessions alter circulating hormones and cytokines in HIV-infected men. [2010.08]
[Genetic basis for skeletal disease. Osteogenesis imperfecta]. [2010.08]
A randomized controlled trial of growth hormone in active pediatric Crohn disease. [2010.08]
Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile. [2010.07]
The GH-2004 project: the response of IGF1 and type III pro-collagen to the administration of exogenous GH in non-Caucasian amateur athletes. [2010.07]
Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction. [2010.07]
Substrate utilization during exercise and recovery at moderate altitude. [2010.07]
|
